Hookipa Pharma’s (HOOK) “Neutral” Rating Reiterated at HC Wainwright

Hookipa Pharma (NASDAQ:HOOK)‘s stock had its “neutral” rating restated by analysts at HC Wainwright in a research report issued on Friday,Benzinga reports.

Other research analysts have also recently issued research reports about the stock. JMP Securities lowered their target price on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 21st. Royal Bank of Canada downgraded Hookipa Pharma from an “outperform” rating to a “sector perform” rating and lowered their price objective for the company from $48.00 to $2.00 in a research report on Friday, December 20th.

Hookipa Pharma Trading Down 1.6 %

NASDAQ HOOK opened at $1.86 on Friday. Hookipa Pharma has a 12 month low of $1.75 and a 12 month high of $10.50. The stock has a market cap of $22.42 million, a price-to-earnings ratio of -0.50 and a beta of 0.71. The company’s 50 day moving average is $2.52 and its two-hundred day moving average is $4.14.

Hedge Funds Weigh In On Hookipa Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC increased its holdings in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after acquiring an additional 108,844 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Hookipa Pharma by 38.4% in the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after purchasing an additional 83,800 shares during the last quarter. Finally, Ikarian Capital LLC purchased a new stake in shares of Hookipa Pharma in the third quarter worth about $228,000. Institutional investors own 63.88% of the company’s stock.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.